FDA panel votes against MDMA for PTSD, setting up hurdle to approval

Nigeria News News

FDA panel votes against MDMA for PTSD, setting up hurdle to approval
Nigeria Latest News,Nigeria Headlines
  • 📰 CBSHealth
  • ⏱ Reading Time:
  • 9 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 7%
  • Publisher: 51%

FDA advisers cited a variety of concerns with the trials submitted by Lykos Therapeutics as part of the application.

Potential approval of MDMA to treat post-traumatic stress disorder hit a major hurdle Tuesday, as a panel of the Food and Drug Administration's outside advisers voted against the treatment.The committee voted nine against, two in favor, on the question of whether there was enough data to show the drug was effective in treating PTSD. The drug, which doctors call midomafetamine, is sold illegally as the street drug ecstasy.

Some members raised concerns about the ways the studies were designed and their results, along with the drugmaker's failure to collect data requested by the FDA.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

CBSHealth /  🏆 480. in US

Nigeria Latest News, Nigeria Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA panel to consider psychedelic party drug MDMA, or molly, for PTSDFDA panel to consider psychedelic party drug MDMA, or molly, for PTSDThe FDA's panel of independent advisers will on June 4 deliberate whether to recommend approval for the first MDMA-assisted therapy for PTSD, Lykos Therapeutics said.
Read more »

FDA panel to evaluate psychedelic MDMA for treatment of PTSD for first timeFDA panel to evaluate psychedelic MDMA for treatment of PTSD for first timeThe U.S. Food and Drug Administration held a meeting to discuss a therapy based on the psychedelic drug MDMA for patients with post-traumatic stress disorder for the first time.
Read more »

Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationPsychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD.
Read more »

Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationPsychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD
Read more »

Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationPsychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD.
Read more »

Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationPsychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD.
Read more »



Render Time: 2025-08-28 00:14:43